Sugi Predict

Sugi Predict / Compounds / SCHEMBL1849181

SCHEMBL1849181

SCHEMBL1849181

CNC[N]c1ccccn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HRH3 Q9Y5N1 1/20 0.44
▸ LMNA P02545 3/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ TAAR1 Q96RJ0 1/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ ADRA2A P08913 4/20 0.42
▸ ADRA2B P18089 4/20 0.42
▸ ADRA2C P18825 4/20 0.42
▸ MAOA P21397 2/20 0.42
▸ MAOB P27338 2/20 0.42
▸ PLAU P00749 1/20 0.42
▸ NOS3 P29474 2/20 0.41
▸ NOS1 P29475 2/20 0.41
▸ NOS2 P35228 2/20 0.41
▸ TDP1 Q9NUW8 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ HSP90AA1 P07900 1/20 0.37
▸ MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1629938 0.77 — —
SCHEMBL7713660 0.73 NOS3 (0.46) LMNAALDH1A1ALOX15ADRA2AADRA2B
SCHEMBL1850336 0.72 MAOA (0.46) ADRA2AADRA2BADRA2CMAOAMAOB
SCHEMBL6603664 0.71 NOS3 (0.44) LMNAALDH1A1ALOX15ADRA2AADRA2B
SCHEMBL7047083 0.69 MAOA (0.48) LMNAALDH1A1ADRA2AADRA2BADRA2C
SCHEMBL1850348 0.69 ADRA2A (0.48) LMNAALDH1A1ADRA2AADRA2BADRA2C
SCHEMBL2235378 0.69 NOS3 (0.42) ALDH1A1ADRA2AADRA2BADRA2CMAOA
SCHEMBL10634493 0.69 ADRA2A (0.44) LMNAALDH1A1ADRA2AADRA2BADRA2C
SCHEMBL1851035 0.69 ADRA2A (0.40) ALDH1A1ADRA2AADRA2BADRA2CMAOA
SCHEMBL967362 0.69 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242116-B2 Fused thiazole derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2012-08-14 — — US disclosed
EP-2035436-B1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2011-05-25 — — EP disclosed
US-20100137302-A1 Fused Thiazole Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-06-03 — — US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 — — WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 — — WO disclosed
WO-2009071888-A1 PYRROLOTHIAZOLES AS PI3-KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 — — WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 — — WO disclosed
EP-2035436-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-18 — — EP disclosed
WO-2008001076-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2008-01-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137302-A1 Fused Thiazole Derivatives as Kinase Inhibitors PI4KA, PDPK1, PIK3CA HRH3 1487/4885LMNA 4511/4885ALDH1A1 2279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.